Classes
DEA Class; Rx
Common Brand Names; Edarbi
- ARBs
Description
Angiotensin II receptor antagonist
Used for hypertension
Black box warning for use during pregnancy
Indications
Indicated for hypertension, either alone or in combination with other antihypertensives
Contraindications
Hypersensitivity
Do not coadminister with aliskiren in patients with diabetes
Adverse Effects
- Diarrhea (2%)
- Nausea
- Asthenia
- Fatigue
- Muscle spasm
- Dizziness
- Postural hypotension
- Cough
- Nausea
- Muscle spasm
- Rash, pruritus, angioedema
Warnings
Abnormally high serum creatinine values more likely reported in patients aged 75 or older
Caution with hyperkalemia
NSAIDs may attenuate antihypertensive response
Coadministration with NSAIDs increase risk of renal impairment including acute renal failure
Pregnancy and Lactation
Pregnancy Category: C (1st trimester); D (2nd and 3rd trimesters)
Discontinue as soon as possible when pregnancy is detected; affects renin-angiotensin system causing oligohydramnios, which may result in fetal injury and/or death
Lactation: unknown whether distributed in breast milk, decide on alternate antihypertensive therapy or do not breastfeed
Maximum Dosage
80 mg/day PO.
80 mg/day PO.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Azilsartan
tablet
- 40mg
- 80mg